Nucana Plc (NCNA)
NASDAQ:NCNA
Top Page
Nucana
(NASDAQ:NCNA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-39.94% Downside)
Action:ReiteratedDate:04/08/26
The score is primarily held down by weak financial performance (pre-revenue losses and ongoing cash burn) and a negative P/E. Technicals are mixed—some near-term strength above the 20-day average, but negative MACD and price well below longer-term moving averages keep the overall score below average.
Positive Factors
Cash runway into 2029 after financings
A disclosed cash runway into 2029 materially extends the company’s operational visibility and reduces near-term financing pressure. For a clinical-stage biotech, multi-year runway allows continued trial enrollment, regulatory interactions and program refinement without immediate dilution risks, improving execution stability.
Negative Factors
No revenue; large ongoing net losses
A persistent lack of revenue and material net losses mean the company cannot self-fund operations and remains dependent on external capital. Over the medium term this limits strategic optionality, increases dilution risk with future financings, and heightens reliance on clinical success to change the cash flow profile.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway into 2029 after financings
A disclosed cash runway into 2029 materially extends the company’s operational visibility and reduces near-term financing pressure. For a clinical-stage biotech, multi-year runway allows continued trial enrollment, regulatory interactions and program refinement without immediate dilution risks, improving execution stability.
Read all positive factors
Nucana (NCNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.20M
Dividend YieldN/A
Average Volume (3M)174.33K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue GrowthN/A
EPS Growth94.52%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-1.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit215.08
Enterprise Value/Ebitda0.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Nucana Business Overview & Revenue Model
Company Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin...
How the Company Makes Money
null...
Nucana Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -267.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -20.09M | -22.48M | -31.78M | -52.15M | -41.88M |
| Net Income | -28.71M | -19.00M | -27.63M | -32.02M | -40.53M |
Balance Sheet | |||||
| Total Assets | 29.78M | 14.77M | 27.81M | 58.25M | 77.47M |
| Cash, Cash Equivalents and Short-Term Investments | 24.21M | 6.75M | 17.23M | 41.91M | 60.26M |
| Total Debt | 674.81K | 190.00K | 396.00K | 639.00K | 371.00K |
| Total Liabilities | 5.50M | 8.82M | 12.92M | 19.75M | 11.93M |
| Stockholders Equity | 24.28M | 5.95M | 14.89M | 38.50M | 65.55M |
Cash Flow | |||||
| Free Cash Flow | -6.96M | -19.41M | -26.92M | -23.68M | -24.89M |
| Operating Cash Flow | -6.96M | -19.12M | -26.44M | -23.16M | -23.82M |
| Investing Cash Flow | -188.77K | 79.00K | 2.89M | 120.00K | -3.56M |
| Financing Cash Flow | 24.46M | 8.18M | -53.00K | -161.00K | -98.00K |
Nucana Technical Analysis
Neutral
3.33
Price Trends
2.01
Positive
2.80
Negative
4.57
Negative
Market Momentum
-0.06
Negative
59.69
Neutral
81.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCNA, the sentiment is Neutral. The current price of 3.33 is above the 20-day moving average (MA) of 1.70, above the 50-day MA of 2.01, and below the 200-day MA of 4.57, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 59.69 is Neutral, neither overbought nor oversold. The STOCH value of 81.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NCNA.
Nucana Risk Analysis
Nucana disclosed 92 risk factors in its most recent earnings report. Nucana reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing. Q4, 2023
2.
Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our product development programs, and could subject us to liability. Q4, 2023
3.
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. Q4, 2023
Nucana Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $7.01M | -1.38 | -60.33% | ― | 13.30% | 22.70% | |
49 Neutral | $8.20M | -0.34 | -253.43% | ― | ― | 94.52% | |
49 Neutral | $10.50M | -0.67 | -87.05% | ― | -62.75% | 23.87% | |
40 Underperform | $6.23M | -1.04 | -49.00% | ― | 47.17% | 26.84% |
* Healthcare Sector Average
NCNA
Nucana
1.97
-148.03
-98.69%
XBIO
Xenetic Biosciences
3.06
0.76
33.04%
IMRN
Immuron
0.79
-0.91
-53.35%
APRE
Aprea Therapeutics
0.92
-0.63
-40.90%
Nucana Corporate Events
NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029
Mar 19, 2026
NuCana on March 19, 2026 reported its fourth quarter and full-year 2025 results, highlighting clinical progress with its ProTide-based oncology pipeline and a strengthened balance sheet. The company said NUC-7738 showed encouraging safety and clin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.